Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11670225 | 0.85 | KMT2A (0.44) | ALDH1A1SMN1; SMN2MAPK1LMNATP53 | |
| SCHEMBL3863960 | 0.82 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNATP53TSHR | |
| SCHEMBL6979204 | 0.80 | MAOB (0.46) | GLAMAOB | |
| SCHEMBL547492 | 0.80 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2LMNATP53TSHR | |
| SCHEMBL7867023 | 0.80 | NR1H2 (0.40) | ALDH1A1SMN1; SMN2MAPK1TSHRGLA | |
| SCHEMBL547805 | 0.79 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2LMNATP53TSHR | |
| SCHEMBL10444592 | 0.78 | TP53 (0.39) | ALDH1A1MAPK1LMNATP53TSHR | |
| SCHEMBL16858004 | 0.76 | NPSR1 (0.41) | ALDH1A1SMN1; SMN2MAPK1LMNATP53 | |
| SCHEMBL6237039 | 0.75 | MLYCD (0.40) | ALDH1A1SMN1; SMN2LMNATP53TSHR | |
| SCHEMBL9119942 | 0.75 | MAOB (0.51) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022400-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021188480-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021102143-A1 | MACROCYCLIC PEPTIDES AS PD-L1 INHIBITORS AND IMMUNOMODULATORS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022400-A1 | IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | ALDH1A1 1602/4885SMN1; SMN2 4465/4885MAPK1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.